Effect of phosphodiesterase type 5 inhibitors on prostate cancer / 国际外科学杂志
International Journal of Surgery
;
(12): 212-216, 2017.
Artículo
en Chino
| WPRIM
| ID: wpr-505658
ABSTRACT
Erectile dysfunction was one of the most frequently postoperative complications after radical prostatectomy,which has been deeply concentrated by patients and urologists,along with more and more people were diagnosed as localized prostate cancer.Widely being used for erectile dysfunction after radical prostatectomy,the efficacy and safety of phosphodiesterase type 5 inhibitors have been confirmed by many clinical studies.However,the influences of phosphodiesterase type 5 inhibitors on the occurrence and progression of cancer are still not completely revealed at present.Additionally,the efficiency of phosphodiesterase type 5 inhibitors on biochemical recurrence after radical prostatectomny is still controversial,though it has been demonstrated that phosphodiesterase type 5 inhibitors is not associated with the occunrence of prostate cancer based on recent clinical studies.We will review the possibly mechanisms of phosphodiesterase type 5 inhibitors in oncologic occurrence,especially in the occurrence of prostate cancer and its biochemical recurrence after radical prostatectomy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
International Journal of Surgery
Año:
2017
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS